Genomic Translation for ALS Care
Sponsor: |
ALS Association |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAQ7026 |
U.S. Govt. ID: |
NCT02795897 |
Contact: |
Marie Likanje: 212-305-2202 / ml4138@cumc.columbia.edu |
The purpose of this study is to look for abnormal genes and gene expression profiles that help determine why a person develops amyotrophic lateral sclerosis (ALS) and related motor neuron diseases (MND) and why their symptoms present and progress with a particular pattern. For up to three years, subjects will be followed every 3 months at the Columbia ALS Center or one of the study centers across the United States. They will undergo neurological examinations, complete questionnaires and have blood drawn.
This study is closed
Investigator
Matthew Harms, MD
Have you been diagnosed with amyotrophic lateral sclerosis, primary lateral sclerosis or related motor neuron disease? |
Yes |
No |
Are you able to travel to Columbia or one of the other sites listed on ClinicalTrials.gov? |
Yes |
No |
Are you willing to have your genome sequenced and shared with other researchers? |
Yes |
No |